Drug Delivery Carriers for Anticancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 20 February 2026 | Viewed by 6
Special Issue Editor
Interests: cancer immunotherapy; drug delivery; gene therapy; cancer immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer continues to be a major cause of death globally, and the drawbacks of standard chemotherapy—such as unintended toxicity, low solubility, and resistance to multiple drugs—emphasize the pressing need for more effective treatment options. Drug delivery vehicles have become important tools for enhancing the therapeutic effectiveness of anticancer drugs by improving their pharmacokinetics, targeting of tumors, and cellular absorption. This Special Issue seeks to showcase recent developments in the creation, synthesis, and use of drug delivery systems—including nanoparticles, liposomes, polymeric micelles, dendrimers, and protein-based carriers—specifically designed for cancer treatment. We welcome original research and reviews addressing both preclinical and translational aspects of targeted delivery, controlled release, tumor microenvironment responsiveness, and combination therapies. Special attention will also be given to the role of delivery route, biodistribution, and imaging-guided theranostics in optimizing anticancer efficacy.
I look forward to receiving your contributions.
Dr. David Větvička
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery systems
- cancer therapy
- nanoparticles
- tumor targeting
- controlled release
- theranostics
- liposomes
- protein nanocarriers
- polymeric micelles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
